Zhang 2006.

Methods	Randomized trial Eligible patients Stage III and IV NSCLC Age > 65 years Karnofsky PS ≥ 60% Life expectation > 3 months Adequate renal and hepatic function No evidence of brain metastasis
Participants	P arm: 30 participants CisP arm: 34 participants CarP arm: 32 participants Median age of study population: 70 years; 51 with stage IIIB and 45 stage IV disease. PS at baseline not informed. No geriatric data scales collected
Interventions	P arm: paclitaxel 60 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks CisP arm: cisplatin 30 mg/m2 i.v. infusion on days 2 to 4 and paclitaxel 60 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks CarP arm: carboplatin AUC5 i.v. infusion on day 2 and paclitaxel 60 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks
Outcomes
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information on random sequence generation
Allocation concealment (selection bias)	Unclear risk	No information on allocation concealment
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome	Unclear risk	No information on blinding of assessors. Study considered to have unclear impact on mortality outcomes
Blinding of outcome assessment (detection bias) Other outcomes	High risk	No information on blinding of assessors for other outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of attrition bias
Selective reporting (reporting bias)	Low risk	No evidence of reporting bias
Other bias	Unclear risk	No separate analysis on participants > 70 years